Ga68-FAPI-46

Phase 1Small molecule

MMayo Clinic

Ga68-FAPI-46 is one of 52 small molecule programs targeting Crohn's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseRecruiting

Crohn's DiseasePhase 1

Recruiting

Competition

Competitive Landscape

74 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

28 2

Humira

Novartis

Approved

22 3

Entyvio

Takeda

Approved

13 4

Omvoh

Eli Lilly

Approved

8 5

Trexall

Jazz Pharmaceuticals

Approved

1 6

Mycobutin

Rocaltrol

Calciferol

Levulan

Sun Pharmaceutical Industries, Inc.

Lamprene

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Crohn's Disease

NCT07273188

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease

Recruiting·MMayo Clinic·Phase 1·NCT07273188·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga68-FAPI-46. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga68-FAPI-46 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga68-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMayo Clinic

Ga68-FAPI-46

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News